Kathleen H Hong1, Eric J Forman2, Marie D Werner3, Kathleen M Upham4, Christina L Gumeny4, Ayesha D Winslow4, Thomas J Kim2, Richard T Scott2. 1. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers-Robert Wood Johnson Medical School, Basking Ridge, New Jersey; Reproductive Medicine Associates of New Jersey, Basking Ridge, New Jersey. Electronic address: khong@rmanj.com. 2. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers-Robert Wood Johnson Medical School, Basking Ridge, New Jersey; Reproductive Medicine Associates of New Jersey, Basking Ridge, New Jersey. 3. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers-Robert Wood Johnson Medical School, Basking Ridge, New Jersey. 4. Reproductive Medicine Associates of New Jersey, Basking Ridge, New Jersey.
Abstract
OBJECTIVE: To determine whether endometrial hCG infusion at the time of human blastocyst transfer impacts implantation rates. DESIGN: Randomized double-blinded placebo-controlled trial. SETTING: Academic. PATIENT(S): Infertile couples with the female partnerless than 43 years old (n = 300) undergoing fresh or frozen ET of one or two blastocysts. INTERVENTION(S): Patients undergoing ET were randomized into either a treatment or a control group. The treatment group received an infusion of 500 IU of hCG diluted in ET media. The control group received a sham infusion of ET media. Infusions were done using a separate catheter less than 3 minutes before actual ET. MAIN OUTCOME MEASURE(S): Sustained implantation rate: ongoing viable gestation (primary outcome) and ongoing pregnancy rate (secondary outcome). RESULT(S): A total of 473 blastocysts were transferred into 300 patients. There were no differences between the two groups in sustained implantation rate (48.1% in the hCG group, 44.2% in the control group) or ongoing pregnancy rate (58.8% in the hCG group, 52.0% in the control group). CONCLUSION(S): Endometrial infusion of hCG at the time of blastocyst ET does not improve sustained implantation rates. CLINICAL TRIAL REGISTRATION NUMBER: NCT01643993.
RCT Entities:
OBJECTIVE: To determine whether endometrial hCG infusion at the time of humanblastocyst transfer impacts implantation rates. DESIGN: Randomized double-blinded placebo-controlled trial. SETTING: Academic. PATIENT(S): Infertile couples with the female partner less than 43 years old (n = 300) undergoing fresh or frozen ET of one or two blastocysts. INTERVENTION(S): Patients undergoing ET were randomized into either a treatment or a control group. The treatment group received an infusion of 500 IU of hCG diluted in ET media. The control group received a sham infusion of ET media. Infusions were done using a separate catheter less than 3 minutes before actual ET. MAIN OUTCOME MEASURE(S): Sustained implantation rate: ongoing viable gestation (primary outcome) and ongoing pregnancy rate (secondary outcome). RESULT(S): A total of 473 blastocysts were transferred into 300 patients. There were no differences between the two groups in sustained implantation rate (48.1% in the hCG group, 44.2% in the control group) or ongoing pregnancy rate (58.8% in the hCG group, 52.0% in the control group). CONCLUSION(S): Endometrial infusion of hCG at the time of blastocyst ET does not improve sustained implantation rates. CLINICAL TRIAL REGISTRATION NUMBER: NCT01643993.
Authors: Michael R Strug; Renwei Su; James E Young; William G Dodds; Valerie I Shavell; Patricia Díaz-Gimeno; Maria Ruíz-Alonso; Carlos Simón; Bruce A Lessey; Richard E Leach; Asgerally T Fazleabas Journal: Hum Reprod Date: 2016-04-26 Impact factor: 6.918
Authors: Barbara Wirleitner; Maximilian Schuff; Pierre Vanderzwalmen; Astrid Stecher; Jasmin Okhowat; Libor Hradecký; Tomáš Kohoutek; Milena Králícková; Dietmar Spitzer; Nicolas H Zech Journal: Reprod Biol Endocrinol Date: 2015-07-04 Impact factor: 5.211